RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.84
+0.07 (+3.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.77
Open1.76
Bid1.48 x 100
Ask1.81 x 400
Day's Range1.75 - 1.87
52 Week Range1.72 - 7.70
Volume133,923
Avg. Volume222,195
Market Cap7.83M
Beta1.40
PE Ratio (TTM)N/A
EPS (TTM)-8.05
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE15 days ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • PR Newswire23 days ago

    BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

    Unlike other SCI drugs in clinical development that target growth inhibition in the central nervous system (CNS), BA-434 targets intrinsic barriers to axon regeneration.  After neurotrauma, neurons in the central nervous system do not spontaneously regenerate their injured axons.  Intrinsic barriers to regeneration refer to the diminished ability of adult CNS neurons to regenerate.  PTEN is known to be an intrinsic barrier to regeneration and BA-434 uses RXi's self-delivering RNA interference therapeutic platform to block PTEN expression.

  • Business Wire23 days ago

    BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

    BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (RXII), it is the recipient of a grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the agency’s SBIR Phase II funding program. This two-year grant provides funding for further development of BioAxone’s preclinical candidate BA-434, a novel sd-rxRNA® compound that targets PTEN for the treatment of spinal cord injury (SCI). After neurotrauma, neurons in the central nervous system do not spontaneously regenerate their injured axons.

  • ACCESSWIRElast month

    Sangamo Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space

    This Wednesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Riot Blockchain Inc. (NASDAQ: RIOT), RXi Pharmaceuticals Corp. (NASDAQ: RXII), Sage Therapeutics Inc. (NASDAQ: SAGE), and Sangamo Therapeutics Inc. (NASDAQ: SGMO).All you have to do is sign up today for this free limited time offer by clicking the link below. Castle Rock, Colorado-based Riot Blockchain Inc.'s stock finished Tuesday's session 0.91% higher at $7.80 with a total trading volume of 296,284 shares.

  • PR Newswire2 months ago

    RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

    - Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP), a topical immunomodulator that works by initiating a T-cell response. MARLBOROUGH, Mass., May 18, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the positive results of its Phase 2 clinical trial, RXI-SCP-1502. The primary effectiveness objectives were met as shown by high levels of immunotherapeutic response and therapeutic response.

  • ACCESSWIRE2 months ago

    Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RXII earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Rxi Pharmaceuticals Corp Earnings Call

  • Zacks Small Cap Research2 months ago

    RXII: Partner Relationships in TILs to Drive Future Value

    RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Trade Desk Inc (NASDAQ: TTD ) stock soared nearly ...

  • MarketWatch2 months ago

    RXi Pharma shares surge 10% premarket after news of partnership with Iovance

    RXi Pharmaceuticals Corp. said Friday it has entered a research partnership with Iovance Biotherapeutics Inc. , under which it will explore potential synergies between RXi's sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer. The news sent RXi's shares up 10% premarket. RXi's compounds use an Adoptive Cell Transfer, or ACT, approach, which involves the use of immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded or processed to express tumor-binding receptors.

  • PR Newswire2 months ago

    RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors

    MARLBOROUGH, Mass., May 11, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) announced today that it has entered into a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer. Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, stated: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology.

  • PR Newswire2 months ago

    RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

    - Reduced cash burn per quarter by 20% from $2.5 million to $2 million - Expect to expand external collaborations in the coming months in IO and ACT - Publication in Molecular Therapy on self-delivering ...

  • PR Newswire2 months ago

    RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

    MARLBOROUGH, Mass., May 8, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it was granted a patent from the United States Patent and Trademark Office (USPTO) for the methods of use of sd-rxRNAs targeting Connective Tissue Growth Factor (CTGF) for the treatment or prevention of fibrotic disorders, including skin fibrosis (USPTO Patent #: 9,963,702 B2). This patent includes RXI-109 and its use in dermal scarring, for which the safety and efficacy was shown in a recent Phase 2 clinical trial with statistically significant outcomes for improved visual appearance for RXI-109 treated scar over control.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference

    MARLBOROUGH, Mass., May 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it will present at the 2018 New York Oncology Investment Conference being held May 8-9, 2018 in New York City.  This conference is designed specifically for life science impact investors and provides an intimate setting with a highly screened group of companies and key opinion leaders in the field of oncology. Dr. Bulock will highlight the Company's sd-rxRNA platform and the ongoing internal and external programs that leverage the self-delivering attributes of its therapeutic compounds in the development of cell-based therapies to treat cancer.

  • ACCESSWIRE3 months ago

    Blog Exposure - Codexis Entered into Strategic Collaboration with Porton Pharma Solutions

    Stock Monitor: RXi Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Codexis, Inc. (NASDAQ: CDXS ). If you want ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018

    MARLBOROUGH, Mass., April 24, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will report its financial results for the first quarter ended March 31, 2018, and provide a business update on May 10, 2018 after the close of the U.S. financial markets. RXi Pharmaceuticals Corporation (RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach.

  • Reuters3 months ago

    Norway's PCI Biotech sees promising data ahead of key study -CEO

    Norwegian drug maker PCI Biotech has seen promising results from its bile duct cancer study ahead of a key second phase, but will need extra capital or a partnership to finalise a treatment, its chief executive told Reuters. Developing the fimaCHEM platform, combining light-based, photochemical technology with its fimaporfin drug, PCI seeks to treat patients who have inoperable tumours. "We are currently in an extension of phase one, scheduled to be finished in the second half of 2018, and then we are ready to start the pivotal phase two almost immediately," Chief Executive Per Walday said in an interview at the company's headquarters.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma

    - Scientists demonstrate the potential of improving therapy with patient-derived tumor infiltrating lymphocytes (TILs) by applying RXi's novel sd-rxRNA compounds specific to PD-1. Targeting the PD-1/PD-L1 ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering

    MARLBOROUGH, Mass., April 11, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today the closing of its previously announced registered direct offering of shares of common stock priced at-the-market for gross proceeds of approximately $4.9 million. RXi issued 1,510,604 shares of common stock, par value $0.0001 per share, at a price of $3.15 per share. Additionally, in a concurrent private placement offering, RXi issued unregistered warrants to purchase a total of 1,132,953 shares of common stock, representing 75% of the shares of common stock purchased in the registered offering.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market

    MARLBOROUGH, Mass., April 9, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,510,604 shares of its common stock, at a purchase price per share of $3.24375, for gross proceeds of approximately $4.9 million, in a registered direct offering priced at-the-market. Additionally, RXi has also agreed to issue to the investors unregistered warrants to purchase up to 1,132,953 shares of common stock. The warrants have an exercise price of $3.15 per share of common stock, shall be exercisable immediately and will expire on the earlier of five and one-half years from the issuance date and 5 years from the date a registration statement registering the shares of common stock underlying the warrants becomes effective.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...

  • Zacks Small Cap Research4 months ago

    RXII: TIL Program Moving Forward while Waiting on Partnerships

    RXi reported revenues of $15,000 for the year from grants related to BioAxone’s work in spinal cord injury, compared to $19,000 in revenues in 2016. Research and development expenses were $5.4 million for the full year, flat with the prior period’s amount. The addition of the immuno-oncology program from MirImmune was offset by lower spending on clinical trial related expenses as patient visits in each of the company’s ongoing clinical trials came to an end.

  • PR Newswire4 months ago

    RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference

    Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of RXII earnings conference call or presentation 26-Mar-18 9:00pm GMT

    Q4 2017 Rxi Pharmaceuticals Corp Earnings Call

  • PR Newswire4 months ago

    RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights

    MARLBOROUGH, Mass. , March 26, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering ...